View source for 18552141. SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION simplified abstract (The Regents of the University of California)

=SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Kole T. Roybal of San Francisco CA (US)|Kole T. Roybal of San Francisco CA (US)]][[Category:Kole T. Roybal of San Francisco CA (US)]]

[[:Category:Iowis Zhu of San Francisco CA (US)|Iowis Zhu of San Francisco CA (US)]][[Category:Iowis Zhu of San Francisco CA (US)]]

[[:Category:Raymond Liu of San Francisco CA (US)|Raymond Liu of San Francisco CA (US)]][[Category:Raymond Liu of San Francisco CA (US)]]

==SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18552141 titled 'SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION

==Simplified Explanation==
This patent application discusses a new class of receptors designed to control gene expression in response to specific molecules. These receptors have unique features that make them useful for various applications, including cancer treatment.

* The receptors are engineered with a stop-transfer sequence and a cleavable transmembrane domain.
* Compositions and methods for producing these receptors are provided.
* Nucleic acids encoding the receptors are included, along with genetically modified host cells.
* The technology can be used to modulate cell activity and treat diseases like cancer.

==Key Features and Innovation==
* Novel receptors with a stop-transfer sequence and cleavable transmembrane domain.
* Ability to control gene expression in response to specific ligands.
* Potential for targeted treatment of diseases like cancer.
* Versatile applications in modulating cell activity.

==Potential Applications==
The technology can be applied in:
* Cancer treatment
* Gene therapy
* Drug development
* Biomedical research

==Problems Solved==
* Targeted modulation of gene expression
* Specific treatment of diseases like cancer
* Enhanced control over cell activity

==Benefits==
* Precise gene regulation
* Potential for personalized medicine
* Improved treatment outcomes
* Versatile applications in research and therapy

==Commercial Applications==
===Potential Commercial Uses and Market Implications===
This technology has potential applications in:
* Pharmaceutical industry for drug development
* Biotechnology companies for research and development
* Clinical settings for personalized medicine approaches

==Prior Art==
Information on prior art related to this technology is not provided in the abstract.

==Frequently Updated Research==
There is no information on frequently updated research related to this technology.

==Questions about New Class of Receptors Engineered to Modulate Transcriptional Regulation==
===What are the specific features of the new receptors mentioned in the patent application?===
The new receptors have a stop-transfer sequence and a cleavable transmembrane domain, allowing for ligand-dependent modulation of gene expression.

===How can this technology be applied in cancer treatment and other biomedical fields?===
This technology can be used to target specific cells or pathways involved in diseases like cancer, offering a more precise and effective treatment approach.


==Original Abstract Submitted==

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. In particular, the new receptors contain a heterologous stop-transfer-sequence and a γ-secretase cleavable transmembrane domain. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.



[[Category:A61K39/00]]
[[Category:A61K38/00]]
[[Category:A61K45/06]]
[[Category:A61K48/00]]
[[Category:C07K14/47]]
[[Category:C07K14/485]]
[[Category:C07K14/705]]
[[Category:C07K14/715]]
[[Category:C07K16/28]]
[[Category:C07K16/30]]
[[Category:C07K16/32]]
[[Category:C07K16/40]]
[[Category:C12N5/0783]]
[[Category:C12N9/16]]
[[Category:CPC_A61K39/464482]]